BR112012024120A2 - sarms e método de uso dos mesmos - Google Patents

sarms e método de uso dos mesmos

Info

Publication number
BR112012024120A2
BR112012024120A2 BR112012024120A BR112012024120A BR112012024120A2 BR 112012024120 A2 BR112012024120 A2 BR 112012024120A2 BR 112012024120 A BR112012024120 A BR 112012024120A BR 112012024120 A BR112012024120 A BR 112012024120A BR 112012024120 A2 BR112012024120 A2 BR 112012024120A2
Authority
BR
Brazil
Prior art keywords
sarms
Prior art date
Application number
BR112012024120A
Other languages
English (en)
Inventor
D Miller Duane
T Dalton James
Kearbey Jeffrey
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of BR112012024120A2 publication Critical patent/BR112012024120A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112012024120A 2010-03-23 2011-03-22 sarms e método de uso dos mesmos BR112012024120A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/730,094 US8309603B2 (en) 2004-06-07 2010-03-23 SARMs and method of use thereof
PCT/US2011/029336 WO2011119544A1 (en) 2010-03-23 2011-03-22 Sarms and method of use thereof

Publications (1)

Publication Number Publication Date
BR112012024120A2 true BR112012024120A2 (pt) 2017-05-30

Family

ID=44673565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024120A BR112012024120A2 (pt) 2010-03-23 2011-03-22 sarms e método de uso dos mesmos

Country Status (12)

Country Link
US (3) US8309603B2 (pt)
EP (1) EP2549865A4 (pt)
JP (2) JP6199182B2 (pt)
CN (1) CN102905526A (pt)
AU (1) AU2011232660B2 (pt)
BR (1) BR112012024120A2 (pt)
CA (1) CA2793999C (pt)
MX (1) MX2012010972A (pt)
NZ (1) NZ602568A (pt)
RU (2) RU2015149196A (pt)
WO (1) WO2011119544A1 (pt)
ZA (1) ZA201207937B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
PL2054049T3 (pl) * 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
RU2012134351A (ru) * 2010-01-11 2014-02-20 ДЖиТиЭкс, ИНК. Способы лечения дисфункции мейбомиевых желез
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
CA2853965A1 (en) * 2011-11-03 2013-05-10 Gtx, Inc. Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
KR102122941B1 (ko) 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
NZ707174A (en) * 2012-09-27 2018-10-26 Aratana Therapeutics Inc Compositions and methods of use of an inappetance-controlling compound
MX2016008283A (es) 2013-12-23 2016-09-08 Bcn Peptides Sa Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.
CN107205991A (zh) 2015-01-28 2017-09-26 阿莱塔纳治疗学股份有限公司 增重化合物的组合物及其长期使用方法
US10221911B2 (en) 2016-07-19 2019-03-05 Beijingwest Industries Co., Ltd. Twin-tube hydraulic damper with a vibration suppressing device
US10578183B2 (en) 2017-01-24 2020-03-03 Beijingwest Industries Co., Ltd. Twin-tube hydraulic damper with a vibration suppressing device
KR101949481B1 (ko) * 2018-05-04 2019-05-02 (주)케이앤씨바이오 사료섭취 증진제 조성물 및 그 제조방법
CN110679773A (zh) * 2019-10-31 2020-01-14 华南农业大学 盐酸吡格列酮和l-肌肽在制备鸡饲料或其添加剂中的应用
CN114557315B (zh) * 2022-02-11 2022-12-20 中国农业大学 一种降低动物胃产甲烷量的方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
LU88769I2 (fr) * 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
FR2697841B1 (fr) 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
CA2247946C (en) 1996-04-04 2006-10-03 Takeda Chemical Industries, Ltd. Anticachectic composition
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6492554B2 (en) * 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DK0967987T3 (da) 1997-03-11 2003-09-22 Aeterna Lab Inc Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
WO1998053826A1 (en) 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
EP1114144A1 (en) 1998-09-16 2001-07-11 Oncopharmaceutical, Inc. Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
IL148192A0 (en) 1999-10-14 2002-09-12 Bristol Myers Squibb Co Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure
KR100826485B1 (ko) 1999-10-14 2008-05-02 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
CZ20021340A3 (cs) 1999-10-19 2002-08-14 Nobex Corporation Způsoby asymetrické přípravy enantiomerů acylanilidů, jejich derivátů a meziproduktů pro uvedené přípravy
AU2619501A (en) 1999-10-27 2001-06-06 Nobex Corporation Resolution of intermediates in the synthesis of substantially pure bicalutamide
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1299094A2 (en) * 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
ATE423092T1 (de) 2000-08-24 2009-03-15 Univ Tennessee Res Foundation Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
CA2422137A1 (en) * 2000-09-14 2003-03-13 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
US7318972B2 (en) * 2001-09-07 2008-01-15 Itm Power Ltd. Hydrophilic polymers and their use in electrochemical cells
JP4605557B2 (ja) 2001-12-06 2011-01-05 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EA200901492A1 (ru) 2002-02-07 2010-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm)
EA013818B1 (ru) 2002-02-28 2010-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Полизамещённые селективные модуляторы рецептора андрогенов и способы их применения
IL163743A0 (en) 2002-02-28 2005-12-18 Univ Tennessee Res Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
CN1652786A (zh) 2002-03-13 2005-08-10 麦克公司 作为雄激素受体调节剂的氟代4－氮杂甾体衍生物
AU2003287075A1 (en) 2002-10-15 2004-05-04 Gtx, Inc. Treating obesity with selective androgen receptor modulators
AU2003287079A1 (en) * 2002-10-16 2004-05-04 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
EP1594490A4 (en) 2003-01-22 2006-03-22 Gtx Inc TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM)
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005036980A1 (en) 2003-10-07 2005-04-28 Eli Lilly And Company Liquid formulations of ractopamine
EP2476415A3 (en) 2003-10-14 2012-08-29 University of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
TW200523235A (en) 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
GB0328905D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
MXPA06000119A (es) 2003-12-16 2006-03-21 Gtx Inc Profarmacos de moduladores receptores de androgenos selectivos y metodos de uso de los mismos.
MXPA06013958A (es) 2004-06-07 2007-03-15 Univ Tennessee Res Foundation Moduladores del receptor de androgenos selectivo metodos para utilizar los mismos.
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
EP2425715B1 (en) 2005-08-31 2014-03-05 University of Tennessee Research Foundation Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
RU2435756C2 (ru) 2006-03-03 2011-12-10 Орион Корпорейшн Избирательные андрогенные рецепторные модуляторы
EA018258B1 (ru) 2006-07-12 2013-06-28 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенный ациланилид и содержащие его композиции и способы лечения
US7550505B2 (en) * 2006-07-24 2009-06-23 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
PL2054049T3 (pl) * 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania

Also Published As

Publication number Publication date
AU2011232660A1 (en) 2012-10-18
CA2793999C (en) 2018-08-21
RU2015149196A (ru) 2019-01-14
MX2012010972A (es) 2013-06-13
CA2793999A1 (en) 2011-09-29
US20100249228A1 (en) 2010-09-30
US20130035387A1 (en) 2013-02-07
JP6199182B2 (ja) 2017-09-20
JP6078127B2 (ja) 2017-02-08
US8669286B2 (en) 2014-03-11
CN102905526A (zh) 2013-01-30
ZA201207937B (en) 2013-06-26
AU2011232660B2 (en) 2014-10-23
EP2549865A4 (en) 2015-11-04
US8309603B2 (en) 2012-11-13
US20140221479A1 (en) 2014-08-07
JP2015226549A (ja) 2015-12-17
US9278914B2 (en) 2016-03-08
WO2011119544A1 (en) 2011-09-29
NZ602568A (en) 2014-04-30
JP2013521830A (ja) 2013-06-13
RU2571421C2 (ru) 2015-12-20
EP2549865A1 (en) 2013-01-30
RU2012144842A (ru) 2014-04-27

Similar Documents

Publication Publication Date Title
BR112012024120A2 (pt) sarms e método de uso dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BR112013014119A2 (pt) novos moduladores e métodos de uso
BR112014012590A2 (pt) anticorpos anti-cd98 e métodos de uso dos mesmos
BR112014009006A2 (pt) compostos heterocíclicos e métodos de uso dos mesmos
BR112013017980A2 (pt) polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
BR112013013167A2 (pt) inibidores de bromodomínio e usos dos mesmos
BR112013018333A2 (pt) sistemas e métodos de âncora ajustável
BRPI0917891A2 (pt) antagonistas de pd-1 e métodos de utilização dos mesmos
BR112013009489A2 (pt) aparelho e método de conexão
BR112013026410A2 (pt) compostos antimicrobianos e métodos de preparação e uso dos mesmos
FI20105901A0 (fi) Laite ja menetelmä
CO6930362A2 (es) Compuesto heterocíclico y su uso
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
BR112012031232A2 (pt) método, dispositivo e uso
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
CO6862148A2 (es) Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112014003774A2 (pt) inibidores de dyrk1 e usos dos mesmos
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112013014235A2 (pt) anticorpos anti-ccr4 e usos dos mesmos
BRPI1006857A2 (pt) agentes de limpeza para limpeza de poços e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL